Reovirus: viral therapy for cancer 'as nature intended'

Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54. doi: 10.1016/j.clon.2008.04.018. Epub 2008 Jun 25.

Abstract

Oncolytic viruses are tumour selective and able to lyse cancer cells after infection. Reovirus is an example of a wild-type oncolytic virus and is currently being investigated as a potential novel therapy for cancer. This overview gives a brief description of what is known about reovirus biology and summarises the preclinical data related to its oncolytic ability. The completed and ongoing clinical trials involving reovirus, both as a single agent and in combination with chemotherapy and radiotherapy, will be reviewed and their results discussed. Many of these clinical studies are being conducted by centres in the UK.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic*
  • Humans
  • Neoplasms / therapy*
  • Oncolytic Virotherapy / methods
  • Oncolytic Virotherapy / trends*
  • Orthoreovirus, Mammalian / genetics
  • Orthoreovirus, Mammalian / growth & development
  • Orthoreovirus, Mammalian / physiology*